If you are interested in learning more about the YES-P clinical trial, please contact your doctor.

The purpose of the YES-P trial is to determine if treatment with TheraSphere® compared to standard-of-care sorafenib therapy improves survival time and is safe.29,30

Eligible participants for this trial are patients with inoperable HCC and blockage of the portal vein, i.e., PVT.

The trial will involve approximately 320 patients at up to 25 sites worldwide, including North America, Europe, and Asia.29,30

Principal Investigators:
  • Vincent Mazzaferro, MD   Istituto Nazionale dei Tumori, Milan, Italy
  • Riad Salem, MD           Northwestern University, Chicago, US